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Nucleic acid ampliﬁcation techniques (NAATs) have been demonstrated to make signiﬁcant
improvements in the diagnosis of tuberculosis (TB), particularly in the time to diagnosis and the
diagnosisofsmear-negativeTB.TheBDProbeTecstranddisplacementampliﬁcation(SDA)system
for the diagnosis of pulmonary and non-pulmonary tuberculosis was evaluated. A total of 689
samples were analysed from patients with clinically suspected TB. Compared with culture, the
sensitivity and speciﬁcity for pulmonary samples were 98 and 89%, and against ﬁnal clinical
diagnosis 93 and 92%, respectively. This assay has undergone limited evaluation for non-
respiratory samples and so 331 non-respiratory samples were tested, identifying those specimens
thatwerelikelytoyieldausefulresult.ThesewereCSF(n ¼ 104),ﬁneneedleaspirates(n ¼ 64)and
pus (n ¼ 41). Pleural ﬂuid (n ¼ 47) was identiﬁed as a poor specimen. A concern in using the SDA
assay was that low-positive samples were difﬁcult to interpret; 7.8% of specimens fell into this
category.Indeed,64%ofthediscrepantresults,whencomparedtoﬁnalclinicaldiagnosis,couldbe
assignedaslow-positive samples.Specimentypedidnotpredictlikelihoodofasamplebeinginthe
low-positive zone. Although the manufacturers do not describe the concept of a low-positive zone,
we have found that it aids clinical diagnosis.
INTRODUCTION
Nucleic acid ampliﬁcation techniques (NAATs) have been
established in the diagnosis of tuberculosis, making signiﬁ-
cant improvements in the time to diagnosis with beneﬁts
both for the individual patient and in the provision of
services. It has been shown that the addition of molecular
techniques to our mycobacterial diagnostic service reduced
the time to conﬁrmed diagnosis from a mean of 37.5t o2 2
days(Daviesetal.,1999).Rapiddiagnosisreducesthecostsof
management of multidrug-resistant-tuberculosis, with esti-
mated savings of between £50000 and £150000 per annum
being achieved following early detection (Drobniewski et al.,
2000).ManyNAATshavebeenemployedsuccessfullyforthe
detection of Mycobacterium tuberculosis (Huggett et al.,
2003). Several commercial systems exist and are in routine
use, for example AMPLICOR (Roche diagnostics; Beavis
et al., 1995), Gen-Probe (Gene-Probe; Gamboa et al., 1998),
ligase chain reaction (Abbot; Lindbrathen et al., 1997),
RealArtM.tuberculosisPCRkit(Artus)andtheBDProbeTec
SDA system (Becton Dickinson; Down et al., 1996) adopted
inthisstudy.TheBDProbeTecisasemi-automatedreal-time
system which allows simultaneous ampliﬁcation and detec-
tionofM.tuberculosistargetDNAIS6110usingampliﬁcation
primers and ﬂuorescently labelled probe.
Commercialsystemsprovidebeneﬁtsofqualityassurancefor
reagents, user friendly formats and automated handling of
large numbers. However, they are often only fully evaluated
for speciﬁc clinical specimens and indications, and ampliﬁ-
cation methods for M. tuberculosis are commonly only
validated on smear-positive respiratory samples. Non-
pulmonary tuberculosis represents a tougher diagnostic
challenge. We therefore performed a prospective evaluation
of the BDProbeTec system for diagnosis of both non-
pulmonary and pulmonary samples. The BDProbeTec sys-
tem is marketed as a qualitative system, providing a positive
or negative result. However, numerical data are produced
Article number = 45780 Doctopic is: diagnos
Abbreviations: FNA, ﬁne needle aspirates; NAAT, nucleic acid
ampliﬁcation techniques; SDA, strand displacement ampliﬁcation; TB,
tuberculosis.and a positive result has a value of .3400 MOTA (Metric
Other Than Acceleration). During the course of this evalua-
tion we noted that the samples with positive SDA results
,40000 MOTA were responsible for the majority of
diagnostic anomalies and so we extended the analysis to
investigate the results in this ‘low-positive zone’.
METHODS
Specimens. Specimens were obtained prospectively from those sub-
mitted routinely to the Molecular Diagnostic Service of the Royal Free
Hospital between and including January 2001 and December 2002.
Molecular analysis was performed on all those patients in whom the
clinician managing the case suspected tuberculosis and requested a M.
tuberculosis NAAT.
Microbiological methods. Specimens were stored at 4 8C prior to
decontamination. Respiratory specimens were treated with an equal
volume of N-acetyl-L-cysteine (NALC)-NaOH (ﬁnal concentration
2%) for 15 min at room temperature and were neutralized with sterile
phosphate buffer (0.067 M, pH 6.8). After centrifugation at 3000 g for
30 min, the pellet was resuspended in 10 ml sterile distilled water and
furthercentrifugedat3000 gfor30 min.Halfthedepositwasinoculated
into the culture medium and the remaining half subjected to SDA
investigation.
Liquid non-respiratory specimens were centrifuged at 3000 g for
30 min. Half the resultant pellet was inoculated into culture medium
and half submitted to SDA. Similarly, following homogenization in a
sterile Grifﬁths tube homogenizer, tissues were divided into two equal
portions. Pellets were resuspended in 2.0 ml phosphate buffer and
subjected to both culture and SDA analysis.
All specimens were screened microscopically after concentration using
theAuraminestainwithpositiveresultsconﬁrmedusingZeihl–Nielsen
staining. Culture was performed using the MBAlert 3D (bioMe ´rieux)
liquid culture system following the manufacturer’s instructions.
Molecular methods. Specimens were treated according to the man-
ufacturer’s instructions. In brief, a volume of 100–500 l decontami-
nated specimen was washed with 1 ml wash buffer (BD-SDA buffer 1)
prior to centrifugation in a microfuge at 12200 g for 3 min. The
supernatant was decanted and mycobacteria killed by heating the pellet
to 105 8C for 30 min. DNA was released from cells in the deposit by
resuspension in 100 l lysis buffer (BD-SDA buffer 2), followed by
sonicationinasoftpolymertubeat65 8Cfor45 min.Sampleswerethen
neutralized by addition of 600 l BD-SDA neutralization buffer.
A 150 l aliquot of the DNA extract was added to a priming well
containing dehydrated primers and probes, in the microtitre plate
supplied. To ensure complete rehydration of reagents the plate was
incubated at room temperature for 20 min. This priming mix was then
incubated at 72.5 8C for 10 min. In a separate microtitre plate,
ampliﬁcation wells containing enzymes, dNTPs and buffer were
activated by heating to 54 8C for 10 min. Ampliﬁcation was activated
by the addition of 100 l of the priming mix to the corresponding
ampliﬁcation well and mixing. Plates were then transferred to the
ProbeTec analyser.
Eachassayrunincludespositiveandnegativecontrolsandeachtestwell
containsaninternalcontrol.Samplesthatgaveaﬂuorescencereadingof
.3400 MOTA were regarded as positive.
Clinical data. Specimens were only entered into the study if a minimal
clinical dataset was available (patient identiﬁers and specimen date,
sample type and anatomical site, SDA assay, smear and culture results,
symptomatic and radiological evidence of tuberculosis). A ﬁnal clinical
diagnosis of tuberculosis was conﬁrmed by cross reference to the
Statutory Infectious Diseases Notiﬁcation records.
Statistical analysis. Analysis was performed on the basis of each
specimen or sample and not on the basis of patient. Sensitivity and
speciﬁcity of the assay was calculated for each specimen type using the
formula described previously by Motulsky (1995).
RESULTS
Over the course of this study a total of 358 respiratory and
331 non-respiratory specimens from 307 patients were
investigated. Multiple specimens (2–5/patient) were re-
ceived from 132 patients, these included sampling of the
same site on separate occasions as well as sampling of
multiple sites on the same occasion. Each specimen was
treatedseparatelyinthisanalysis,asaspecimenrepresentsan
independent diagnostic event. In assigning a ﬁnal diagnosis
all specimens were considered together with microbiological
and clinical data. The respiratory specimens consisted of
sputum (169) and bronchial washings/lavages (189). Non-
respiratory specimens included cerebrospinal ﬂuid (CSF;
104), ﬁne needle aspirates (FNA; 64), ascitic ﬂuid (18), pus
(41),pleuralﬂuid(47),ﬂuids(17)andotherspecimens(40).
Theresultsofculture,SDA,acid-fastbacilli(AFB)smearand
ﬁnal clinical diagnosis are summarized in Tables 1 and 2.
Ninety-ﬁve patients had a clinical diagnosis of pulmonary
tuberculosis and 69 had a diagnosis of extra-pulmonary
tuberculosis. On culture, 83/358 respiratory samples were
positive for M. tuberculosis (Table 1) a further 14 samples
grew non-tuberculosis mycobacteria (NTM), these were
Table 1. SDA, culture, smear and clinical diagnosis (CD) of 358 respiratory samples (189 bronchial washings,
169 sputum)
Mtb SDA
result
Culture-positive Culture-negative
Smear-positive Smear-negative Smear-positive Smear-negative
CD: not TB CD: TB CD: not TB CD: TB CD: not TB CD: TB CD: not TB CD: TB
Positive 0 48 0 33 0 2 19 9
Negative 0 0 0200 2 4 0 5
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Mycobacterium fortuitum (5), Mycobacterium xenopi (3)
and two unidentiﬁed environmental mycobacteria. Of the
non-respiratory samples 54/331 were culture-positive for M.
tuberculosis (Table 2) and one specimen grew M. avium. For
respiratory samples 111/358 (31%) were positive by SDA
andfornon-respiratorysamples60/331(18%)werepositive
by SDA.
Using the manufacturer’s cut-off of 3400 MOTA, the
sensitivity and speciﬁcity for respiratory samples was 98
and89%,respectively,comparedtoculture(Table3).When
compared to clinical diagnosis the sensitivity was reduced
but the speciﬁcity increased (Table 3).
An analysis of assay performance was undertaken for each
non-respiratory specimen type where there were adequate
sample numbers for valid interpretation (Table 3). When
compared to culture, CSF samples gave good sensitivity and
speciﬁcity (100 and 95%). The assay characteristics for FNA
and pus specimens were adequate to provide useful data,
however, pleural ﬂuid samples had very poor sensitivity
(30%).
All other non-respiratory sites were evaluated on the basis of
potential clinical relevance and individual case histories.
Review of the false-positive results identiﬁed 42 of which 27
(64%) fell between ,3400 MOTA and ,40000 MOTA,
designated the low-positive zone. The remaining 15 had
values above 40000 MOTA. Forty-six per cent of the low-
positivezonespecimens(27/58)werediscrepantandofthese
15 were respiratory specimens. The remaining 12 non-
respiratory specimens came from a range of sites with no
single type predominating (pleural ﬂuid, 3; ﬂuid, 2; FNA, 2;
ascitic ﬂuid, 1; CSF, 3; pus, 1).
Table 2. SDA, culture, smear and clinical diagnosis (CD) of 331 non-respiratory samples
Specimen type Mtb SDA
result
Culture-positive Culture-negative
Smear-positive Smear-negative Smear-positive Smear-negative
CD: not TB CD: TB CD: not TB CD: TB CD: not TB CD: TB CD: not TB CD: TB
Ascitic ﬂuid (n ¼ 18) Positive 0 0 0 2 0 0 0 0
Negative 0 0 0 2 0 0 12 2
CSF (n ¼ 104) Positive 0 1 0 1 0 0 3 2
Negative 0 0 0 0 0 0 91 6
Fluids (n ¼ 17) Positive 0 2 0 2 0 0 0 0
Negative 0 0 0 2 0 0 10 1
FNA (n ¼ 64) Positive 0 3 0 5 0 1 4 0
Negative 0 0 0 3 0 1 46 1
Pleural ﬂuid (n ¼ 47) Positive 0 0 1 2 0 0 3 0
Negative 0 0 3 4 0 0 29 5
Pus (n ¼ 41) Positive 1 1 0 10 1 1 2 2
Negative 2 1 1 1 1 0 16 1
Others (n ¼ 40) Positive 0 1 0 1 0 0 4 4
Negative 0 0 1 1 1 0 24 3
Table 3. Sensitivity(sens.),speciﬁcity(spec.),positivepredictivevalue(PPV)andnegativepredictivevalue(NPV)ofMtbSDAforvarious
specimen types compared to smear, culture and ﬁnal diagnosis for each sample
Sample Smear Culture Final diagnosis
Sens.
(%)
Spec.
(%)
PPV NPV Sens.
(%)
Spec.
(%)
PPV NPV Sens.
(%)
Spec.
(%)
PPV NPV
Respiratory specimens 100 80 45 100 98 89 73 99 93 92 81 97
CSF* 100 94 14 100 100 95 29 100 40 97 57 94
FNA 80 85 31 98 73 91 62 94 64 92 69 90
Pleural ﬂuid 100 87 0 100 30 92 50 83 18 89 33 78
Pus 100 58 22 83 71 75 66 78 78 83 78 87
*Note of caution: of 104 CSF samples tested only two were positive.
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The purpose of NAAT in the diagnosis of tuberculosis is to
identify patients requiring treatment rapidly. Using the
methods in this way means that applying them to specimens
that are smear-positive provides the best diagnostic yield.
However, such apolicy islessrational thanitﬁrstappears,as
often the clinical presentation, examination and radiology
mean that a positive smear is adequate to make a presump-
tive diagnosis. This is especially true when infections with
non-tuberculosis mycobacteria such as M. avium intracellu-
larearelesslikelywithpatientsonhighlyactiveantiretroviral
therapy (HAART). We have previously shown that results
from smear-negative patients have the biggest impact on
treatment decisions (Conaty et al., 2004). Thus, the applica-
tionofNAATtospecimensthataresmear-negativeorfroma
non-pulmonary source is important.
The BDProbeTec SDA system is now well established in the
diagnosis of respiratory tuberculosis and the data presented
here reﬂect both the manufacturer’s data and that of other
groups (Barrett et al. 2002; Mazzarelli et al., 2003). For
respiratorysamples,SDAimprovedsensitivity(Table3)over
smear alone, which has a sensitivity of 58% against culture
and 53% against ﬁnal clinical diagnosis. In this study, the
speciﬁcity of the SDA was notably low (89%), when com-
pared to other NAATs, although it is comparable to the test
characteristics published by the manufacturers (91%). We
have previously reported that there is cross-reactivity be-
tween the target (IS6110) and mycobacteria other than
tuberculosis (McHugh et al., 1997), such cross-reactivity
may contribute to the decreased speciﬁcity of the test. This
view is supported by the observation that speciﬁcity against
culture is good in those samples that are likely to have
fewer competing bacteria (CSF, FNA and pleural ﬂuid) as
compared to pus and respiratory specimens. Of course it
should be noted that ‘ﬁnal diagnosis‘ includes an element
of bias, as the SDA result often contributes to the ﬁnal
diagnosis.
Inthisstudywehaveidentiﬁedsamplesthatarelow-positive
(.3400–, 40000MOTA),whichformed 7.8%ofallspeci-
mens. Of the discrepant results, when compared to ﬁnal
clinicaldiagnosis,64%couldbe assignedtothe low-positive
zone. There were 54 samples in this low-positive zone, of
which 46% were discrepant. Specimen type did not predict
thelikelihood of asamplebeing in thelow-positive zone,15/
27discrepantresultswererespiratorysamples,theremaining
12 samples were from a wide range of non-respiratory sites
with no single site being over-represented (P . 0.05).
Although the manufacturers do not describe the concept of
a low-positive zone, we have found that its introduction has
been an aid to interpretation for clinical diagnosis. These
samples represent a small proportion of the total, but our
experience is that they demand a disproportionate effort to
achieve a satisfactory ﬁnal diagnosis. The implications for a
patient of being treated inappropriately for tuberculosis are
substantial.Thus, weproposethat anysamplewith results in
the low-positive zoneis automatically repeatedand a further
specimen sought. Only if all three results are concordant
shouldaresultbereported.Thebiologicalsigniﬁcanceofthe
false-positive results in the low-positive zone remains un-
clear, the presence of low levels of M. tuberculosis DNA as a
result of environmental exposureor non-viable infection are
both possibilities. The critical point is that these patients did
not go on to develop clinical disease which emphasizes the
need to view the molecular test result within the context of
the whole clinical picture.
In this 2-year review of our practice we have identiﬁed those
non-respiratory samples for which an SDA result may be
interpreted with some conﬁdence. CSF is a critical specimen
with good sensitivity and speciﬁcity as compared to smear
and culture (Table 3). It should be noted that this analysis is
based on 2/104 positive samples. The manufacturers report
a sensitivity of 125 c.f.u. ml 1 for the SDA assay, this is
tenfold greater than the likely number of organisms in CSF,
thus the test is being used at the limit of its analytical
sensitivity in this context, and this may contribute to the
poor sensitivity in comparison to ﬁnal diagnosis (40%).
This reﬂects the importance of non-microbiological mar-
kers, such as CSF pleocytosis and biochemistry in the
diagnosis of TB meningitis and identiﬁes a role for the
SDA in rapid diagnosis. Recently, Johansen et al. (2004)
described a modiﬁed extraction protocol and subsequent
re-evaluation of the 3400 MOTA cut-off for CSF samples,
this is a promising development that may increase the
sensitivity for this important specimen. The low sensitivity
but high speciﬁcity of the SDA for FNA samples reﬂects
low organism numbers often found in these specimens,
however, the good speciﬁcity makes the test very useful
clinically. Conversely, applying the SDA to pus samples
showed good sensitivity but poor speciﬁcity, thus, although
a negative result may be helpful, the poor speciﬁcity suggests
that SDA should be applied to pus samples with caution.
Pleural ﬂuid is known to be a poor sample for smear and
culture testing due to sampling and dilution effects (Valdes
et al., 2003). This is also the case for SDA testing, sensitivity
of this test for pleural ﬂuids is so low that the test is of
little value.
This is the largest prospective review of NAAT for the
diagnosis of non-respiratory samples. As a result we are able
tofocusourresourcesonthosespecimensthataremostlikely
to yield clinically relevant results. We conﬁrm the value of
NAATtechniquesindiagnosisfromrespiratorysamples,and
particularly enhanced sensitivity from smear-negative speci-
mens (Conaty et al., 2004). Also, we have demonstrated that
certain non-respiratory samples are appropriate for NAAT
diagnosis but there is a signiﬁcant risk of biological false-
positive results and so these tests must be interpreted with
caution.
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